Efficacy and safety of short (≤6 months) versus prolonged (>6 months) dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains uncertain, as therapy must balance ischemic protection against bleeding risk. While prolonged DAPT may enhance antithrombotic efficacy, shorter regimens have been proposed to improve safety. To c...